Monday, Piper Sandler adjusted its price target on shares of Cytek Biosciences Inc (NASDAQ:CTKB), reducing it to $8.50 from $10.00, while maintaining an Overweight rating on the stock. The firm's adjustments were made in light of revised earnings projections for the upcoming years.
The revised estimates by Piper Sandler now set the 2024 expected revenue and earnings per share (EPS) for Cytek Biosciences at $205 million and -$0.09 respectively, a slight improvement from the previous EPS estimate of -$0.10. This forecast is in comparison to a consensus estimate which anticipates slightly higher revenue of $209 million and a positive EPS of $0.05.
For the year 2025, the firm has modified its revenue and EPS projections to $238 million and -$0.01 respectively, a slight decrease from the earlier forecast of $239 million in revenue and a breakeven EPS. The consensus for the same year stands at a more optimistic $248 million in revenue and an EPS of $0.15.
Looking further ahead to 2026, the firm's revenue and EPS estimates have been adjusted to $277 million and $0.11, down from an initial forecast of $280 million in revenue but maintaining the same EPS. This estimate is more conservative compared to the consensus, which projects revenue of $279 million and an EPS of $0.22.
InvestingPro Insights
As Piper Sandler revises its outlook on Cytek Biosciences Inc (NASDAQ:CTKB), investors may find additional context from real-time data and expert analysis. The InvestingPro platform provides a nuanced picture of the company's financial health and future prospects. With a market capitalization of $813.89 million and a striking revenue growth of 20.91% over the last twelve months as of Q1 2023, Cytek Biosciences is showing signs of expansion despite not being profitable during this period.
Two InvestingPro Tips that stand out for Cytek Biosciences are the aggressive share buyback management has undertaken and the company holding more cash than debt on its balance sheet, which could be indicators of confidence from the management and financial resilience respectively. Additionally, analysts on InvestingPro predict that the company will turn profitable this year, aligning with Piper Sandler's positive EPS forecast for 2026.
Investors should note that Cytek Biosciences does not pay a dividend, which may influence investment decisions for those seeking income in addition to growth. For those interested in a deeper dive, there are additional InvestingPro Tips available on the platform. To access these insights and more, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.